These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38839136)

  • 1. Use of SGLT2 Inhibitors in Patients With HF With and Without Type 2 Diabetes: An Endocrinologist's Perspective.
    Butler J; Pessah-Pollack R
    JACC Heart Fail; 2024 Jun; 12(6S):S4-S6. PubMed ID: 38839136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary and Panel Discussion.
    Butler J; Rich J; Pessah-Pollack R; Anderson JE
    JACC Heart Fail; 2024 Jun; 12(6S):S10-S11. PubMed ID: 38839135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing Patients on SGLT2 Inhibitors in Primary Care.
    Butler J; Anderson JE
    JACC Heart Fail; 2024 Jun; 12(6S):S7-S9. PubMed ID: 38839137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of Heart Failure and the Discovery of the Cardioprotective Effects of SGLT2 Inhibitors.
    Butler J; Rich J
    JACC Heart Fail; 2024 Jun; 12(6S):S1-S3. PubMed ID: 38839134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure.
    Ghosh RK; Ghosh GC; Gupta M; Bandyopadhyay D; Akhtar T; Deedwania P; Lavie CJ; Fonarow GC; Aneja A
    Am J Cardiol; 2019 Dec; 124(11):1790-1796. PubMed ID: 31627834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary: SGLT2 inhibitors reduce mortality and heart failure in patients with type 2 diabetes mellitus-is metabolic reprogramming the mechanism for these favorable outcomes?
    Lazar HL
    J Thorac Cardiovasc Surg; 2022 Sep; 164(3):901-904. PubMed ID: 33812677
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
    Imran H; Nester W; Elgendy IY; Saad M
    Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy.
    Anker SD; Usman MS; Butler J
    Circulation; 2022 Jul; 146(4):299-302. PubMed ID: 35877834
    [No Abstract]   [Full Text] [Related]  

  • 10. Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment.
    Packer M
    Am J Med; 2020 Jul; 133(7):781-782. PubMed ID: 32061625
    [No Abstract]   [Full Text] [Related]  

  • 11. SGLT2 Inhibitors in Type 2 Diabetes Mellitus.
    Ferrannini G; Savarese G; Cosentino F
    Heart Fail Clin; 2022 Oct; 18(4):551-559. PubMed ID: 36216485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?
    Savarimuthu S; Harky A
    Expert Opin Pharmacother; 2022 Feb; 23(3):377-386. PubMed ID: 34713764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin for heart failure: is it a class effect?
    Raj GM; Wyawahare M
    Future Cardiol; 2021 Mar; 17(2):355-361. PubMed ID: 32755319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology.
    Mai Z; Li H; Chen G; Chen E; Liu L; Lun Z; Lai W; Zhou C; Yu S; Liu J; Chen S; Chen J; Liu Y
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):713-726. PubMed ID: 34028657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
    Sano M
    J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer M
    Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
    [No Abstract]   [Full Text] [Related]  

  • 17. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding the Role of SGLT2 Inhibitors Beyond Diabetes: A Case-Based Approach.
    Wong E; Nguyen TV
    Sr Care Pharm; 2023 Jun; 38(6):233-238. PubMed ID: 37231576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Vaduganathan M; Januzzi JL
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.